178 related articles for article (PubMed ID: 36735144)
1. Discovery of Small Molecule PARKIN Activator from Antipsychotic/Anti-neuropsychiatric Drugs as Therapeutics for PD: an In Silico Repurposing Approach.
Ibrahim A; Ipinloju N; Atasie NH; Babalola RM; Muhammad SA; Oyeneyin OE
Appl Biochem Biotechnol; 2023 Oct; 195(10):5980-6002. PubMed ID: 36735144
[TBL] [Abstract][Full Text] [Related]
2. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
Kumar S; Chowdhury S; Kumar S
BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
[TBL] [Abstract][Full Text] [Related]
3. Repurposing the inhibitors of MMP-9 and SGLT-2 against ubiquitin specific protease 30 in Parkinson's disease: computational modelling studies.
Alshehri MM; Danazumi AU; Alshammari MK; Bello RO; Alghazwni MK; Alshehri AM; Alshlali OM; Umar HI
J Biomol Struct Dyn; 2024; 42(3):1307-1318. PubMed ID: 37139557
[TBL] [Abstract][Full Text] [Related]
4. In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy.
Gnanaraj C; Sekar M; Fuloria S; Swain SS; Gan SH; Chidambaram K; Rani NNIM; Balan T; Stephenie S; Lum PT; Jeyabalan S; Begum MY; Chandramohan V; Thangavelu L; Subramaniyan V; Fuloria NK
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566187
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Compounds Targeting DJ-1 as Neuroprotectants for Parkinson's Disease by Virtual Screening and In Silico Method.
Sharan S; Kumar P; Ambasta RK
Curr Comput Aided Drug Des; 2021; 17(3):351-359. PubMed ID: 32303174
[TBL] [Abstract][Full Text] [Related]
6. Network metrics, structural dynamics and density functional theory calculations identified a novel Ursodeoxycholic Acid derivative against therapeutic target Parkin for Parkinson's disease.
Naha A; Banerjee S; Debroy R; Basu S; Ashok G; Priyamvada P; Kumar H; Preethi AR; Singh H; Anbarasu A; Ramaiah S
Comput Struct Biotechnol J; 2022; 20():4271-4287. PubMed ID: 36051887
[TBL] [Abstract][Full Text] [Related]
7. Study of the Effects of Nicotine and Caffeine for the Treatment of Parkinson's Disease.
Biswas S; Bagchi A
Appl Biochem Biotechnol; 2023 Jan; 195(1):639-654. PubMed ID: 36121634
[TBL] [Abstract][Full Text] [Related]
8. Prospecting for new catechol-
da Silva IR; Parise MR; Pereira M; da Silva RA
J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671
[TBL] [Abstract][Full Text] [Related]
9. In-silico Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson's disease.
Banerjee R; Kumar M; Gaurav I; Thakur S; Thakur A; Singh K; Karak S; Das R; Chhabra M
Antiinflamm Antiallergy Agents Med Chem; 2021; 20(3):250-263. PubMed ID: 33183209
[TBL] [Abstract][Full Text] [Related]
10. Identification of LRRK2 Inhibitors through Computational Drug Repurposing.
Tan S; Lu R; Yao D; Wang J; Gao P; Xie G; Liu H; Yao X
ACS Chem Neurosci; 2023 Feb; 14(3):481-493. PubMed ID: 36649061
[TBL] [Abstract][Full Text] [Related]
11. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
Johnston TH; Lacoste AMB; Visanji NP; Lang AE; Fox SH; Brotchie JM
Neuropharmacology; 2019 Mar; 147():11-27. PubMed ID: 29907424
[TBL] [Abstract][Full Text] [Related]
12. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
13. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
Hattori N
Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the New Inhibitors by Sulfadiazine and Modified Derivatives of α-D-glucopyranoside for White Spot Syndrome Virus Disease of Shrimp by In Silico: Quantum Calculations, Molecular Docking, ADMET and Molecular Dynamics Study.
Kumer A; Chakma U; Rana MM; Chandro A; Akash S; Elseehy MM; Albogami S; El-Shehawi AM
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744817
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Drug Repurposing for Parkinson's Disease.
Chen X; Gumina G; Virga KG
Curr Med Chem; 2019; 26(28):5340-5362. PubMed ID: 30027839
[TBL] [Abstract][Full Text] [Related]
16. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.
Usui C; Hatta K; Doi N; Kubo S; Kamigaichi R; Nakanishi A; Nakamura H; Hattori N; Arai H
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1704-8. PubMed ID: 21605615
[TBL] [Abstract][Full Text] [Related]
17. Identification of Potential Parkinson's Disease Drugs Based on Multi-Source Data Fusion and Convolutional Neural Network.
Liu J; Peng D; Li J; Dai Z; Zou X; Li Z
Molecules; 2022 Jul; 27(15):. PubMed ID: 35897954
[TBL] [Abstract][Full Text] [Related]
18. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
19. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
20. Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease.
Kalyanaraman B
Redox Biol; 2020 Sep; 36():101665. PubMed ID: 32795938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
